Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 2
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years.
Patruno C, Fabbrocini G, Lauletta G, Boccaletti V, Colonna C, Cavalli R, Neri I, Ortoncelli M, Schena D, Stingeni L, Hansel K, Piccolo V, Di Brizzi V, Potenza C, Tolino E, Bianchi L, Manti S, De Pasquale R, Di Lernia V, Caminiti L, Galli E, Coppo P, Chiricozzi A, De Simone C, Guerriero C, Amoruso FG, Provenzano E, Leonardi S, Licari A, Marseglia GL, Palermo A, Di Pillo S, Russo D, Moschese V, Patella V, Peduto T, Ferreli C, Zangari P, Veronese F, Berti SF, Gruber M, Pezzolo E, Termine S, Satta R, Dragoni F, Esposito M, Fargnoli MC, Chiodini P, Vallone Y, di Vico F, Picone V, Napolitano M. Patruno C, et al. Among authors: amoruso fg. J Dermatolog Treat. 2023 Dec;34(1):2246602. doi: 10.1080/09546634.2023.2246602. J Dermatolog Treat. 2023. PMID: 37580895 Free article.
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Sampogna F, Travaglini M, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: amoruso f. J Clin Med. 2024 Jan 16;13(2):495. doi: 10.3390/jcm13020495. J Clin Med. 2024. PMID: 38256629 Free PMC article.
Risankizumab: Daily Practice Experience of High Need Patients.
Brunasso AMG, Burlando M, Amoruso F, Arancio L, Malara G, Manzo R, Montesu MA, Caldarola G. Brunasso AMG, et al. Among authors: amoruso f. Biomedicines. 2023 Jun 20;11(6):1769. doi: 10.3390/biomedicines11061769. Biomedicines. 2023. PMID: 37371864 Free PMC article.
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis).
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Fabbrocini G, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Sampogna F, Travaglini M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: amoruso f. Front Med (Lausanne). 2023 Jul 3;10:1196966. doi: 10.3389/fmed.2023.1196966. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37469659 Free PMC article.
Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis).
Malagoli P, Dapavo P, Pavia G, Amoruso F, Argenziano G, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dini V, Girolomoni G, Guarneri C, Loconsole F, Narcisi A, Sampogna F, Travaglini M, Costanzo A. Malagoli P, et al. Among authors: amoruso f. Dermatol Ther. 2022 Aug;35(8):e15608. doi: 10.1111/dth.15608. Epub 2022 Jun 8. Dermatol Ther. 2022. PMID: 35638250
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
Narcisi A, Valenti M, Gargiulo L, Ibba L, Amoruso F, Argenziano G, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Franchi C, Girolomoni G, Guarneri C, Loconsole F, Sampogna F, Travaglini M, Malagoli P, Costanzo A. Narcisi A, et al. Among authors: amoruso f. J Eur Acad Dermatol Venereol. 2023 Jan;37(1):93-103. doi: 10.1111/jdv.18594. Epub 2022 Oct 5. J Eur Acad Dermatol Venereol. 2023. PMID: 36156312 Free PMC article.
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis).
Valenti M, Gargiulo L, Ibba L, Malagoli P, Amoruso F, Balato A, Bardazzi F, Burlando M, Carrera CG, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Travaglini M, Costanzo A, Narcisi A. Valenti M, et al. Among authors: amoruso f. Dermatol Ther (Heidelb). 2024 May 15. doi: 10.1007/s13555-024-01182-4. Online ahead of print. Dermatol Ther (Heidelb). 2024. PMID: 38748344
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
Gargiulo L, Ibba L, Cascio Ingurgio R, Malagoli P, Amoruso F, Balato A, Bardazzi F, Brianti P, Brunasso G, Burlando M, Cagni AE, Caproni M, Carrera CG, Carugno A, Caudullo F, Cuccia A, Dapavo P, Di Brizzi EV, Dini V, Gaiani FM, Gisondi P, Guarneri C, Lasagni C, Licata G, Loconsole F, Marzano AV, Megna M, Mercuri SR, Musumeci ML, Orsini D, Ribero S, Ruffo Di Calabria V, Satolli F, Strippoli D, Travaglini M, Trovato E, Venturini M, Zichichi L, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: amoruso f. J Dermatolog Treat. 2024 Dec;35(1):2350760. doi: 10.1080/09546634.2024.2350760. Epub 2024 May 7. J Dermatolog Treat. 2024. PMID: 38714323 Free article.